We recently compiled a list of the Jim Cramer’s Top 12 Must-Watch Stocks. In this article, we are going to take a look at ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has ...

NTx’s new services offering provides faster and more affordable high-integrity, complex mRNA production powered by NTxscribe® ...

( MENAFN - PR Newswire) BARCELONA, Spain, Sept. 16, 2024 /PRNewswire/ -- WestGene Biopharma, a leading innovator in mRNA ...

Cartesian Therapeutics has a strong cash position after a $130 million equity raise, extending its runway to support upcoming ...

Moderna’s recent stock drop reflects investor concerns over the company’s revised financial outlook and strategic shifts. Despite its pioneering role in mRNA technology and promising future prospects, ...

LONDON, UK I 12, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results of a phase II trial (NCT06431607) for its mRNA seasonal ...

Based on the high rate of global immunity and currently available data, the State Surgeon General advises against the use..." ...

Treatment with OTX-2002 led to controlled downregulation of MYC gene expression and resulted in significant inhibition of tumor growth as a ...

Respiratory illnesses like influenza and COVID can change rapidly, requiring the nimble development and delivery of antiviral ...